secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEUROCRINE BIOSCIENCES INC (NBIX)
CIK:        0000914475
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0000914475-23-000078
Event type: litigation
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Neurocrine settles all INGREZZA patent litigations; generic entry starts March 1, 2038
--------------------------------------------------------------------------------

- Resolved patent litigation with Zydus; Zydus can sell generic INGREZZA from Oct 1, 2038 (or earlier under certain circumstances).
- Prior settlements with Sandoz, Teva, and Lupin allow generic entry from March 1, 2038, subject to earlier triggers.
- All ANDA-filing companies now settled, blocking generic competition until at least 2038, a significant IP win.
- Settlements require FTC/DOJ review but are standard in Hatch-Waxman litigation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/914475/000091447523000078/0000914475-23-000078-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/914475/000091447523000078/nbix-20231110.htm
  HTML page:      https://secwatch.observer/filing/0000914475-23-000078

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer